HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+12.21%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$290M
AUM Growth
+$290M
(+5.9%)
Cap. Flow
-$2.16M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32
Top Buys
| 1 |
GE Vernova
GEV
|
$3.75M |
| 2 |
Amgen
AMGN
|
$3.25M |
| 3 |
Protagonist Therapeutics
PTGX
|
$3.07M |
| 4 |
Amazon
AMZN
|
$2.65M |
| 5 |
Edgewise Therapeutics
EWTX
|
$2.37M |
Top Sells
| 1 |
Insmed
INSM
|
$5.94M |
| 2 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$4.02M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$3.97M |
| 4 |
Merus
MRUS
|
$2.14M |
| 5 |
Meta Platforms (Facebook)
META
|
$2.06M |
Sector Composition
| 1 | Healthcare | 46.45% |
| 2 | Technology | 15.69% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Industrials | 4.98% |
| 5 | Financials | 4.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Apellis Pharmaceuticals
APLS
$3.51B
| $1.04M | 0.36% |
35,975
+28,409
| +375% | +$819K |
|
102
CRH
CRH
$75.1B
| $1.03M | 0.36% |
11,100
+1,000
| +10% | +$92.7K |
|
103
Progressive
PGR
$145B
| $1.02M | 0.35% |
+4,000
| New | +$1.02M |
|
104
Vera Therapeutics
VERA
$1.47B
| $973K | 0.34% |
22,010
+12,848
| +140% | +$568K |
|
105
Adobe
ADBE
$148B
| $932K | 0.32% |
1,800
-1,300
| -42% | -$673K |
|
106
First Citizens BancShares
FCNCA
$25.7B
| $920K | 0.32% |
+500
| New | +$920K |
|
|
CNTA
107
Centessa Pharmaceuticals
CNTA
$2.13B
| $737K | 0.25% |
+46,116
| New | +$737K |
|
|
VRNA
108
Verona Pharma
VRNA
$9.18B
| $683K | 0.24% |
23,739
-8,710
| -27% | -$251K |
|
109
Autoliv
ALV
$9.56B
| $672K | 0.23% |
+7,200
| New | +$672K |
|
110
Praxis Precision Medicines
PRAX
$980M
| $630K | 0.22% |
+10,951
| New | +$630K |
|
111
KE Holdings
BEKE
$21.8B
| $607K | 0.21% |
30,507
+6,800
| +29% | +$135K |
|
112
Kymera Therapeutics
KYMR
$3.1B
| $603K | 0.21% |
+12,743
| New | +$603K |
|
113
CG Oncology
CGON
$2.19B
| $594K | 0.2% |
+15,734
| New | +$594K |
|
114
Geron
GERN
$893M
| $578K | 0.2% |
127,284
-52,515
| -29% | -$238K |
|
115
Avidity Biosciences
RNA
$6.12B
| $574K | 0.2% |
+12,504
| New | +$574K |
|
116
JD.com
JD
$44.2B
| $571K | 0.2% |
14,283
-4,900
| -26% | -$196K |
|
117
Trip.com Group
TCOM
$46.6B
| $568K | 0.2% |
9,556
-2,200
| -19% | -$131K |
|
118
Baidu
BIDU
$33.1B
| $567K | 0.2% |
5,386
+1,200
| +29% | +$126K |
|
119
Ocular Therapeutix
OCUL
$2.25B
| $566K | 0.2% |
65,027
+3,168
| +5% | +$27.6K |
|
|
ABVX
120
Abivax
ABVX
$6.32B
| $565K | 0.19% |
49,064
-445
| -0.9% | -$5.13K |
|
121
Li Auto
LI
$24.4B
| $562K | 0.19% |
+21,900
| New | +$562K |
|
122
Soleno Therapeutics
SLNO
$3.56B
| $560K | 0.19% |
+11,085
| New | +$560K |
|
|
ITCI
123
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $548K | 0.19% |
7,496
-16,841
| -69% | -$1.23M |
|
124
Dianthus Therapeutics
DNTH
$781M
| $542K | 0.19% |
+19,808
| New | +$542K |
|
125
Cullinan Oncology
CGEM
$456M
| $534K | 0.18% |
+31,893
| New | +$534K |
|